The Archive · 4 posts

Genedrive PLC

Powering precision medicine 🎯 Genedrive PLC (GDR) is revolutionising genetic diagnostics on the LSE. Join the future of healthcare 🌟

SubscribeRSS JSON

Genedrive Partners with Thermo Fisher Scientific to Launch High-Throughput CYP2C19 Pharmacogenetic Test

Genedrive partners with Thermo Fisher to launch a high-throughput CYP2C19 test for NHS labs, expanding beyond point-of-care into centralised stroke care diagnostics.

June 29, 2026

Browse All

Investing

Genedrive Posts H1 Results with £4.9m Fundraise, Advances NHS and International Commercialisation

Genedrive secures £4.9m funding, eliminates debt, and gains NHS traction for rapid genetic tests, advancing US and international commercialisation.

JoshuaMarch 30, 2026

Investing

genedrive plc FY25 Results: Revenue Doubles Amid Going Concern Warning

Genedrive's FY25 results show revenue doubled to £1.0m, but auditors flag a 'material uncertainty' over going concern due to severe cash pressure.

JoshuaDecember 5, 2025

Investing

Genedrive Plc Doubles Annual Revenue to £1m and Eyes Growth from NHS Reforms

Genedrive doubles FY25 revenue to £1m; strong FY26 visibility & NHS reforms to boost adoption of NICE-recommended point-of-care tests.

JoshuaAugust 11, 2025

Genedrive PLC

Join the newsletter

Genedrive Partners with Thermo Fisher Scientific to Launch High-Throughput CYP2C19 Pharmacogenetic Test

Browse All

Genedrive Posts H1 Results with £4.9m Fundraise, Advances NHS and International Commercialisation

genedrive plc FY25 Results: Revenue Doubles Amid Going Concern Warning

Genedrive Plc Doubles Annual Revenue to £1m and Eyes Growth from NHS Reforms

Get the latest Investment news

Got an investment you want to share?